Conditionally Active Biologics: Transforming Cancer Therapy Corporate Presentation November 2025 Important Notices & Disclaimers This presentation (the "Presentation") by BioAtla, Inc. ("we", "us", "our", "BioAtla", or the "Company") contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, operations and financial conditions, including but not limited to statements we make regarding BioAtla's business plans and prospects; whet ...

BioAtla's CAB Platform and Pipeline - BioAtla is a clinical-stage company focused on transforming cancer therapy with Conditionally Active Biologics (CABs)[9] - The CAB platform maximizes the therapeutic window and has broad applicability in solid tumors[10, 15] - BioAtla has proprietary technology with over 500 issued patents[10] BA3182 (CAB-EpCAM x CAB-CD3 TCE) - BA3182 is in Phase 1 dose escalation, with updated data expected in Q4 2025 and dose expansion planned for 1H 2026[10] - BA3182 targets EpCAM, which is expressed in a high percentage of various cancers, including 81% of breast cancers, 99% of prostate and pancreatic cancers, and 100% of colon cancers[37] - Preliminary data shows objective tumor size reductions in multiple tumor types, including a 13% reduction in intrahepatic cholangiocarcinoma[58, 59] - In a Phase 1 study with subcutaneous dosing (N=22), 91% of patients experienced any adverse events, but most were low-grade and manageable[56] Mecbotamab Vedotin (CAB-AXL-ADC) - Mecbotamab Vedotin (Mec-V) is being developed for mKRAS Non-Small Cell Lung Cancer (NSCLC)[63] - AXL is overexpressed in 70% to 85% of mKRAS NSCLC, driving aggressive tumor characteristics and resistance to therapies[72] - Mec-V at 1.8 mg/kg Q2W showed a 31% overall response rate (confirmed and unconfirmed) and a 67% one-year landmark overall survival in mKRAS NSCLC patients[74] Ozuriftamab Vedotin (CAB-ROR2-ADC) - Ozuriftamab Vedotin (Oz-V) is being developed for HPV+ Oropharyngeal Squamous Cell Carcinoma (OPSCC)[88] - In SCCHN patients, Oz-V at 1.8 mg/kg Q2W showed a 45% overall response rate (confirmed and unconfirmed) and a median overall survival of 11.6 months in p16+ patients[104] - A meeting with the FDA is planned in Q3 2025 to confirm the proposed Phase 3 study design in 2L+ HPV+ OPSCC[10, 120] Evalstotug (CAB-CTLA-4) - Evalstotug is a next-generation adaptation of Ipilimumab, selectively active in the tumor microenvironment to reduce immune-mediated adverse events[122] - In a study of 17 patients treated with Evalstotug at 350 mg in combination with PD-1, the overall response rate was 44%[141] - In unresectable and/or metastatic cutaneous melanoma patients treated with Evalstotug (5 – 14.3 mg/kg) in combination with a PD-1 antibody, the overall response rate was 67% and the disease control rate was 92%[146, 163]